Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06990971

Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment of Chronic Conditions Such as Endometriosis and Related Pathologies: This is an Observational Study Aimed at Shedding Light on Women's Health

Many women's health conditions have limited treatments available and poor outcomes, in part due to the lack of understanding of disease processes and lack of data available. This study aims to build knowledge in women's health by leveraging the information we can gather from menstrual fluid and the uterus. By looking at samples from menstrual fluid and biopsies and associating it with health outcomes of the people donating these samples, we will be able to find new signatures of disease. This can help us find early diagnostic markers, better classify diseases and give us the tools that allow us to build the right models in the lab to find new treatments. By collecting this data, we will be able to identify patterns within given diseases that can help us cure them and derive the cells necessary to model the disease. The study is funded and undertaken by Cycle Therapeutics, a company with the mission of curing endometriosis. All women above the age of 16 will be eligible, although most samples will be collected from those who are menstruating or already undergoing biopsies/surgical tissue removal. Women with endometriosis or suspicion of the disease are encouraged to take part, but participation of people without any symptoms or conditions is important to understand what the base healthy state looks like. Most of the sample processing will be done within Cycle and collection will occur at clinics or remotely, and can be as simple as pouring menstrual fluid from a cup into a tube to ship to Cycle. The study will last four years, during which we hope to build a strong understanding of conditions affecting women. We will be able to provide health insight to donors after each donation, but the greatest value in this study will lie in the new treatments we can discover thanks to our novel understanding.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Menstruating

Exclusion criteria

  • Not menstruating

Treatment and study plan

No Intervention: Observational Cohort

Other

No interventions will be performed specifically for this study. Samples will be collected from menstrual fluid naturally shed or from biopsies and/or operations that are already taking place.

Primary outcomes

  1. Identifying tissue signatures of endometriosis

    Time frame: 1-4 years

    The principal research objective is to identify signatures of endometriosis within the samples collected. These signatures can help us understand:

    • - Whether endometriosis is one disease or many sub-diseases, therefore informing how we treat each patient.
    • - What endometriosis tissue looks like. This will be used to build our lab models that we will use to test therapies on.
    • - What drives progression of the disease. Recurrent measurements will allow us to tease out which processes are involved in disease progression.
    • - How endometriosis cells compare to control cells in a dish. This will be critical to establishing the right read outs for our search of novel drugs that can reverse the disease.

Secondary outcomes

  1. The value of menstrual fluid in health research

    Time frame: 1-4 years

    When collecting the clinical and biological data from donors, we may be able to identify early diagnostic markers of certain particular conditions, or predict the prognosis of others. We may also find a very robust signature of another disease related or unrelated to endometriosis. Our aim is to more broadly assess the descriptive value of menstrual fluid and tissue biopsies.

  2. Menstrual cell potential

    Time frame: 1-4 years

    We will determine the value of cells isolated from menstrual fluid and biopsies in both disease modelling and therapeutic interventions.

Study contacts

Contact information is provided by the study sponsor or research team.

Léa MD Wenger, MA, PhD

CONTACT

[email protected]

+447880894277

Sponsors and collaborators

Lead sponsor

Cycle Therapeutics Ltd

Industry

Registry information

Official study title

Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment of Chronic Conditions Such as Endometriosis and Related Pathologies

Acronym: CYCLE_ENDO

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
May 25, 2025
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.